Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients
Stephen Macfarlane, Timo Grimmer, Ken Teo, Terence J. O’Brien et autres